FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 340:1436-1439 May 6, 1999 Number 18 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Zittoun, R. A. Related Article by Cassileth, P. A.

To the Editor: Cassileth et al. (Dec. 3 issue)¹ report the results of a large study comparing chemotherapy with autologous or allogeneic bone marrow transplantation in the management of acute myeloid leukemia in first remission. Their study showed that autologous or allogeneic bone marrow transplantation offered no advantage over intensive chemotherapy in terms of overall survival. However, the study included patients with a variety of risk factors. Although there is no established prognostic index for acute myeloid leukemia, we believe that most institutions do not perform bone marrow transplantation in patients with either the M2 or the M3 type of . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.